HUE065385T2 - Magnézium tartalmú oxitocin készítmények és felhasználásuk módszerei - Google Patents

Magnézium tartalmú oxitocin készítmények és felhasználásuk módszerei

Info

Publication number
HUE065385T2
HUE065385T2 HUE16735422A HUE16735422A HUE065385T2 HU E065385 T2 HUE065385 T2 HU E065385T2 HU E16735422 A HUE16735422 A HU E16735422A HU E16735422 A HUE16735422 A HU E16735422A HU E065385 T2 HUE065385 T2 HU E065385T2
Authority
HU
Hungary
Prior art keywords
magnesium
methods
containing oxytocin
preparations
oxytocin preparations
Prior art date
Application number
HUE16735422A
Other languages
English (en)
Hungarian (hu)
Inventor
David Yeomans
Dean Carson
Ramachandran Thirucote
Original Assignee
Tonix Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharma Ltd filed Critical Tonix Pharma Ltd
Publication of HUE065385T2 publication Critical patent/HUE065385T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
HUE16735422A 2015-01-07 2016-01-07 Magnézium tartalmú oxitocin készítmények és felhasználásuk módszerei HUE065385T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562100862P 2015-01-07 2015-01-07

Publications (1)

Publication Number Publication Date
HUE065385T2 true HUE065385T2 (hu) 2024-05-28

Family

ID=56285908

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16735422A HUE065385T2 (hu) 2015-01-07 2016-01-07 Magnézium tartalmú oxitocin készítmények és felhasználásuk módszerei

Country Status (24)

Country Link
US (2) US9629894B2 (enExample)
EP (2) EP3242676B1 (enExample)
JP (3) JP7030517B2 (enExample)
KR (1) KR102677904B1 (enExample)
CN (1) CN107847552B (enExample)
AU (3) AU2016205225A1 (enExample)
CA (1) CA2972975A1 (enExample)
DK (1) DK3242676T3 (enExample)
ES (1) ES2963707T3 (enExample)
FI (1) FI3242676T3 (enExample)
HR (1) HRP20231438T1 (enExample)
HU (1) HUE065385T2 (enExample)
IL (1) IL253347B (enExample)
LT (1) LT3242676T (enExample)
MX (1) MX388286B (enExample)
PL (1) PL3242676T3 (enExample)
PT (1) PT3242676T (enExample)
RS (1) RS65034B1 (enExample)
RU (1) RU2017127734A (enExample)
SG (1) SG11201705591PA (enExample)
SI (1) SI3242676T1 (enExample)
SM (1) SMT202400020T1 (enExample)
WO (1) WO2016112205A1 (enExample)
ZA (1) ZA201705176B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7030517B2 (ja) * 2015-01-07 2022-03-07 トライジェミナ， インコーポレイテッド マグネシウム含有オキシトシン製剤および使用の方法
CN115814055A (zh) 2016-04-12 2023-03-21 三叉神经股份公司 含镁催产素制剂和应用方法
EP3681474B1 (en) * 2017-09-11 2025-10-29 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions and methods for nasal administration of drugs to brain and for systemic effect
US11970554B2 (en) 2018-03-01 2024-04-30 Tonix Pharmaceuticals Holding Corp. Labeled oxytocin and method of manufacture and use
US20230414492A1 (en) * 2019-04-02 2023-12-28 Nose To Brain Therapeutics Llc Intranasal delivery of cannabidiol to treat central nervous system disorders
US11241477B2 (en) 2019-08-29 2022-02-08 New York University Oxytocin compositions for treatment of tinnitus
WO2022200568A1 (en) 2021-03-26 2022-09-29 Ot4B Treatment of dysphagia
GB2607333A (en) * 2021-06-03 2022-12-07 Horopito Ltd Pain relief composition
WO2023091469A1 (en) * 2021-11-17 2023-05-25 The Board Of Trustees Of The Leland Stanford Junior University Targeting periosteal tissue for delivery of therapeutics
US20250255930A1 (en) * 2024-02-08 2025-08-14 Maskbegone Llc Methods of treatment of tinnitus using derivatives of oxytocin

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE431291C (de) 1925-03-29 1926-07-08 Contessa Nettel A G Wechselkassette mit herausziehbarer Wechsellade
US1936364A (en) 1930-08-22 1933-11-21 Pfizer Charles & Co Citrate solutions
US2260004A (en) 1939-11-03 1941-10-21 Pfizer Charles & Co Stable soluble magnesium acid citrate
US2938891A (en) 1956-03-30 1960-05-31 Roussel Uclaf Method of making oxytocin and intermediates thereof
US3076797A (en) 1957-07-22 1963-02-05 Roussel Uclaf Process of producing oxytocin and intermediates obtained thereby
US4213968A (en) 1978-06-05 1980-07-22 Coy David Howard Enkephalin derivatives
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4486441A (en) 1982-12-03 1984-12-04 Merrell Toraude Et Compagnie Pseudotropyl halogeno-benzoates and their use in migraine treatment
JPS59163313A (ja) 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
ATE78158T1 (de) 1985-05-22 1992-08-15 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
HU906340D0 (en) 1986-10-13 1991-04-29 Sandoz Ag Synthesis in solid phase for producing peptonic alcohols
KR890006252A (ko) 1987-10-15 1989-06-12 헤르비그 폰 모르체 분말형 폴리펩타이드의 비강내 투여용 조성물 및 투여방법
US4885287A (en) 1988-08-09 1989-12-05 University Of Kentucky Research Foundation Novel method of administering aspirin and dosage forms containing same
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US6407061B1 (en) 1989-12-05 2002-06-18 Chiron Corporation Method for administering insulin-like growth factor to the brain
ATE156704T1 (de) 1989-12-05 1997-08-15 Ramsey Foundation Neurologische wirkstoffe zur nasalen verabreichung an das gehirn
US5460972A (en) * 1991-04-08 1995-10-24 Research Foundation Of The State University Of New York Ionized magnesium2+ concentrations in biological samples
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
GB9203769D0 (en) 1992-02-21 1992-04-08 Sandoz Ltd Improvements in or relating to organic compounds
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
DE4312913A1 (de) 1992-10-23 1994-10-13 Knauf Siegfried Medikamentenzusammensetzung Oxytocin, Vasopressin und alphabetagamma-Endorphine
SE9300937L (sv) 1993-03-19 1994-09-20 Anne Fjellestad Paulsen Komposition för oral administrering av peptider
DE69434418T2 (de) 1993-04-22 2005-12-22 Emisphere Technologies, Inc. Orale Dareichungsform
US5482931A (en) 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
US5837809A (en) 1995-08-11 1998-11-17 Oregon Health Sciences University Mammalian opioid receptor ligand and uses
US6054462A (en) 1994-04-13 2000-04-25 Janssen Pharmaceutica, N.V. Intranasal antimigraine compositions
JP3414539B2 (ja) 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
WO1996020001A1 (en) 1994-12-28 1996-07-04 Teikoku Hormone Mfg. Co., Ltd. Transmucosal preparation
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
CA2247191C (en) * 1996-02-27 2005-01-04 Teijin Limited Powdery composition for nasal administration
DE19627228A1 (de) 1996-07-05 1998-01-08 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
US5914129A (en) 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
US5798266A (en) 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
US5855907A (en) 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
SE9701162D0 (sv) 1997-03-27 1997-03-27 Karolinska Innovations Ab New use II
SE9701161D0 (sv) 1997-03-27 1997-03-27 Karolinska Innovations Ab New use I
AU8333998A (en) 1997-07-15 1999-02-10 Novo Nordisk A/S New use of nociceptin
US6432986B2 (en) 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US20030185761A1 (en) 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6143278A (en) 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US6090368A (en) 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
EP1950224A3 (en) 1998-03-09 2008-12-17 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6068999A (en) 1998-06-25 2000-05-30 Hendrix; Curt Dietary supplement for supporting cerebrovascular tone and treating migraine headaches
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
JP2002531490A (ja) 1998-12-09 2002-09-24 カイロン コーポレイション 中枢神経系に薬剤を投与するための方法
JP2002531489A (ja) 1998-12-09 2002-09-24 カイロン コーポレイション 中枢神経系への神経栄養剤の投与
US7273618B2 (en) 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
US6139861A (en) 1999-01-14 2000-10-31 Friedman; Mark Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm
KR20020016831A (ko) 1999-06-16 2002-03-06 나스텍 파마수티컬 컴퍼니 인코포레이티드 비내용 모르핀을 함유하는 의약 조성물 및 그 제조방법
JP2001002589A (ja) 1999-06-18 2001-01-09 Teijin Ltd 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物
JP2001089359A (ja) 1999-09-24 2001-04-03 Toko Yakuhin Kogyo Kk 鎮痛成分の点鼻用ゲルまたはゾル製剤
AU8003800A (en) * 1999-10-08 2001-04-23 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
CA2325106A1 (en) 1999-12-06 2001-06-06 Stanley L. Gore Compositions and methods for intranasal delivery of active agents to the brain
DE60021760T2 (de) 1999-12-09 2006-06-08 Chiron Corp., Emeryville Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
ATE290856T1 (de) 1999-12-16 2005-04-15 Dermatrends Inc Hydroxide freisetzende verbindungen zum verbessern der hautdurchlässigkeit
US6413499B1 (en) 2000-01-06 2002-07-02 Bryan M. Clay Methods and kits for maxillary dental anesthesia by means of a nasal deliverable anesthetic
JP2001233787A (ja) 2000-02-04 2001-08-28 Patents Exploitation Co Bv 小・中サイズのペプチド含有薬学的組成物
EP1121935B1 (en) 2000-02-04 2008-08-13 Patents Exploitation Company B.V. Pharmaceutical composition containing a small or medium size peptide
WO2001079263A1 (en) 2000-04-14 2001-10-25 Nippon Shinyaku Co., Ltd. Peptide derivatives and medicinal compositions
AU2001257326A1 (en) 2000-04-28 2001-11-12 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
US7084126B1 (en) 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
AU2001262992A1 (en) 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
IL137820A (en) 2000-08-10 2009-06-15 S I S Shulov Inst For Science Pharmaceutical composition for topical administration comprising an analgesic peptide
AU2002211688A1 (en) 2000-10-13 2002-04-29 Chiron Corporation Method for treating ischemic events affecting the central nervous system
US20070112052A9 (en) 2001-01-05 2007-05-17 Larry Caldwell Methods and compositions for treating headache pain with topical NSAID compositions
DE60236496D1 (de) 2001-03-23 2010-07-08 Einstein Coll Med Verfahren zur erhöhung der analgetischen wirkung und zur verringerung der unerwünschten exitatorischen wirkungen von bimodalisch wirksamen opioidagonisten durch die hemmung von gm1-gangliosid
US20020169102A1 (en) 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
JP2004532849A (ja) 2001-04-20 2004-10-28 カイロン コーポレイション 中枢神経系へのポリヌクレオチド薬剤の送達
US7820688B2 (en) 2001-04-27 2010-10-26 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
SE0102184D0 (sv) 2001-06-19 2001-06-19 Uvnaes Moberg Kerstin New subject-matter
AU2002349513B2 (en) 2001-11-26 2007-10-18 Asubio Pharma Co., Ltd. Medicinal compositions for nasal absorption
US20030104085A1 (en) 2001-12-05 2003-06-05 Yeomans David C. Methods and compositions for treating back pain
JP2005524649A (ja) 2002-02-25 2005-08-18 カイロン コーポレーション Ｍｃ４−ｒアゴニストの鼻腔内投与
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7074426B2 (en) 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US20040105889A1 (en) 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
CA2785889A1 (en) 2002-04-22 2003-10-30 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase c
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
ES2348604T3 (es) 2002-04-29 2010-12-09 Euro-Celtique S.A. Péptidos conformacionalmente restringidos que se unen al receptor orl-1.
WO2003093816A2 (en) 2002-05-02 2003-11-13 Bayer Healtchare Ag Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
EP2283864A1 (en) 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
WO2004019875A2 (en) 2002-08-30 2004-03-11 Board Of Regents, The University Of Texas System Non-invasive methods to identify agents for treating pain
ITMI20022022A1 (it) 2002-09-24 2004-03-25 Girolamo Calo' Analoghi di nocicettina.
ES2353690T3 (es) 2002-10-03 2011-03-04 Neuropharmacology Services, Llc Oxitocina para su uso en el tratamiento del autismo y del trastorno de asperger.
WO2004062563A2 (en) 2003-01-16 2004-07-29 Université de Lausanne Methods for screening for therapeutic agents that are useful in the treatment of oxytocin and vasopressin-related disorders
US20070016968A1 (en) 2003-02-19 2007-01-18 Stephanos Kyrkanides Treatment of pain through expression of opioid receptors
ES2315455T3 (es) 2003-03-27 2009-04-01 Pantarhei Bioscience B.V. Uso de estrogenos para el tratamiento de infertilidad en maniferos machos.
WO2005046569A2 (en) 2003-04-08 2005-05-26 Biotempt B.V. Pharmaceutical compositions for the treatment of sars
GB0319119D0 (en) * 2003-08-14 2003-09-17 Optinose As Delivery devices
US20050153885A1 (en) 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
US20050228023A1 (en) 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
WO2005115370A2 (en) 2004-04-23 2005-12-08 The Regents Of The University Of California Compounds and methods for treating non-inflammatory pain using pparalpha agonists
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
US7151084B2 (en) * 2004-12-27 2006-12-19 Miller Landon C G Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes
CA2588292C (en) 2004-12-01 2019-01-15 Health Protection Agency Non-cytotoxic protein conjugates
WO2006091332A2 (en) 2005-02-23 2006-08-31 Alza Corporation Intranasal administration of active agents to the central nervous system
CN101193626A (zh) 2005-03-11 2008-06-04 益德威士医药股份有限公司 奥曲肽的受控释放制剂
US20060252685A1 (en) 2005-05-04 2006-11-09 Gould Jeffrey D Treatment for sleep apnea
EP1928484B1 (en) * 2005-08-26 2010-02-24 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
US9125833B2 (en) 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US9023793B2 (en) 2006-09-29 2015-05-05 Retrophin, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
US8142803B2 (en) 2007-03-22 2012-03-27 Magceutics, Inc. Magnesium compositions and uses thereof for neurological disorders
US9808509B2 (en) 2007-06-08 2017-11-07 Healthpartners Research Foundation Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
JP2009073744A (ja) 2007-09-19 2009-04-09 Saitama Medical Univ 片頭痛の予防治療剤
EP2161030A1 (en) 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
JP5467785B2 (ja) 2009-03-25 2014-04-09 大塚製薬株式会社 抗鳥インフルエンザウイルス抗体の産生促進剤
KR20180052610A (ko) * 2009-07-27 2018-05-18 노시셉터 엘엘씨 통증 치료 방법
JP5491119B2 (ja) 2009-10-02 2014-05-14 日東電工株式会社 薬物含有微粒子を含む医薬組成物およびその製造方法
US20130130985A1 (en) * 2010-04-01 2013-05-23 Paul Alewood Oxytocin peptide analogues
AU2011264416A1 (en) 2010-06-07 2013-01-10 The University Of Queensland Nociceptin mimetics
WO2012016229A2 (en) * 2010-07-30 2012-02-02 The Regents Of The University Of California Oxytocin treatment to improve memory and modify blood glucose
JO3400B1 (ar) 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
US20120252894A1 (en) * 2011-04-01 2012-10-04 Giniatullin Rashid Compounds for alleviating pain and stress in fetus and newborn
SE536091C2 (sv) 2011-04-14 2013-04-30 Pep Tonic Medical Ab Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
EP2908840A1 (en) * 2012-10-12 2015-08-26 Peptonic Medical AB Novel use of a composition comprising oxytocin
US20140147519A1 (en) 2012-11-26 2014-05-29 Larry A. MCPHAIL Migraine Treatment
JP7030517B2 (ja) * 2015-01-07 2022-03-07 トライジェミナ， インコーポレイテッド マグネシウム含有オキシトシン製剤および使用の方法

Also Published As

Publication number Publication date
JP7030517B2 (ja) 2022-03-07
JP7756953B2 (ja) 2025-10-21
JP7455402B2 (ja) 2024-03-26
ES2963707T3 (es) 2024-04-01
US20160193282A1 (en) 2016-07-07
IL253347B (en) 2022-03-01
CN107847552A (zh) 2018-03-27
HK1252942A1 (zh) 2019-06-06
US11389473B2 (en) 2022-07-19
AU2020286221A2 (en) 2021-04-15
RU2017127734A3 (enExample) 2019-06-03
AU2020286221A1 (en) 2021-01-07
MX388286B (es) 2025-03-19
JP2018502856A (ja) 2018-02-01
CN107847552B (zh) 2022-07-01
KR20180023884A (ko) 2018-03-07
IL253347A0 (en) 2017-09-28
US9629894B2 (en) 2017-04-25
EP3242676A4 (en) 2018-10-17
EP4331670A2 (en) 2024-03-06
AU2020286221B2 (en) 2024-06-20
EP4331670A3 (en) 2024-05-29
AU2016205225A1 (en) 2017-08-17
PT3242676T (pt) 2023-12-06
SG11201705591PA (en) 2017-08-30
SI3242676T1 (sl) 2024-02-29
DK3242676T3 (en) 2023-11-06
WO2016112205A1 (en) 2016-07-14
PL3242676T3 (pl) 2024-07-15
NZ734097A (en) 2024-07-05
US20170368095A1 (en) 2017-12-28
RS65034B1 (sr) 2024-02-29
EP3242676B1 (en) 2023-10-04
SMT202400020T1 (it) 2024-03-13
AU2024203428A1 (en) 2024-06-13
JP2024059989A (ja) 2024-05-01
EP3242676A1 (en) 2017-11-15
NZ771693A (en) 2024-07-05
BR112017014545A2 (pt) 2018-01-16
FI3242676T3 (fi) 2023-11-07
MX2017008913A (es) 2018-04-30
LT3242676T (lt) 2024-01-25
RU2017127734A (ru) 2019-02-07
JP2022009901A (ja) 2022-01-14
ZA201705176B (en) 2023-01-25
KR102677904B1 (ko) 2024-06-21
HRP20231438T1 (hr) 2024-06-07
CA2972975A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
IL323656A (en) Neoantigens and methods for using them
IL286316A (en) New micro-dystrophins and related method of use
ZA202004919B (en) Anti-tigit antigen-binding proteins and methods of use thereof
IL259931A (en) Neoantigen identification, manufacture, and use
IL256652A (en) Therapeutic compositions, combinations, and methods of use
HUE046756T2 (hu) Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei
ZA201708589B (en) Factor xi antibodies and methods of use
HUE046000T2 (hu) Antiproferatív vegyületek és alkalmazásuk módszerei
HUE047784T2 (hu) Anti-TIM3 antitestek és alkalmazási eljárások
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
HUE061576T2 (hu) Kevert allergén készítmények és eljárások alkalmazásukra
HUE065385T2 (hu) Magnézium tartalmú oxitocin készítmények és felhasználásuk módszerei
HUE055473T2 (hu) Difluormetil-aminopiridinek és difluormetil-aminopirimidinek
HUE055199T2 (hu) Oxiszterolok és alkalmazási eljárásaik
LT3341027T (lt) Transfekcijos kompleksai ir jų panaudojimo būdai
HUE054093T2 (hu) Anti-HtrA1 antitestek és azok alkalmazási eljárásai
HUE055700T2 (hu) Szülés utáni depresszió elleni módszerek és készítmények
HUE049732T2 (hu) Kanrenoát és exenatid kombinációja
DK3442560T3 (da) Magnesium-indeholdende oxytocinformuleringer og fremgangsmåder til anvendelse